Insightful Insights

Breakthroughs In Gene Editing Allow For The Creation Of Superior Preclinical Oncology Models

Gene editing is getting a lot of attention in the [...]

Patient Derived Xenograft Studies From Wider Varieties Of Patient Sub-Populations Promise Improved Clinical Trial Selection And Design

Around 85% of preclinical drugs entering clinical trials in oncology never make it past Phase 1 because they fail to demonstrate sufficient efficacy due to testing in unselected patient populations 1-3. Many of these failed agents are targeted therapies, meaning that they target specific oncogenic driver mutations. However, not all tumors harbor the same, or even similar, driving mutations – these targeted therapies are often found to be beneficial in very small patient populations which would not be captured in an unselected-patient trial design.

2022-02-16T19:38:31+00:00

OncoRat® PDX Models Highlighted In Drug Discovery News (DDN) Special Report On Cancer: Aiming For Avatars

While advances in in-vitro platforms have allowed researchers to better visually monitor a variety of aspects of tumor biology, a significant limitation of 3D cultured models for patient therapeutic monitoring or “patient avatars” is the lack of important components, such as the influence of surrounding tissues and potential cell-to-cell interactions, when studying cancer progression, treatment responses and outcomes. Patient derived xenograft models or PDX models overcome these limitations and other research challenges and provide a platform that is believed to more closely mimic the patient tumor.

2022-02-16T19:42:22+00:00

Title